Fraudulent procurement defense not substantiated

Quality Med. Care, PC v Progressive Cas. Ins. Co., 2017 NY Slip Op 50999(U)(Civ. Ct. Bronx Co. 2017)

I read this and I think the Court missed the issue, yet arrived at the result it should have.  First issue: a material misrepresentation defense (Ins Law 3105) does not require an intentional misrepresentation.  That said, second issue: proof must be adduced as to the rate difference,  Third issue: assuming it is not an AIP policy (statutory rates).  the underwriting manual must be entered into evidence.

The Court got lost on issue one and briefly addressed issue two (but never ruled on it) and failed to address issue three.

Too many moving pieces on these cases.

Point one: “The record is devoid of what actions, if any, the defendant took in regards to Ms. Murphy’s automobile insurance policy after having actual knowledge that she was residing in Jamaica, New York. Apparently, the defendant subsequent to the automobile accident decided to disclaim payment of Ms. Murphy’s medical bills on the purported basis that at the time the application for insurance was submitted by her that she provided a false residential address.”

Not a real issue.  Estoppel  is generally not a defense to a fraudulent procurement defense.  Perhaps now it is?  There is no case law on the topic.

Second issue: “there is no evidence attesting to her intent”  Irrelevant.

No testimony as to the rate difference:  “The best that this court can surmise, is that there must be a price differential in the policy premiums charged in Rochester, New York and Jamaica, New York, with the latter premiums being higher as this appears to be the motive attributed by defendant to the plaintiff’s assignor”

That is all she wrote on this one.

Legal Significance

Jason Tenenbaum correctly identifies three critical evidentiary deficiencies in Progressive’s case, though the court focused primarily on the first two issues while overlooking the third.

First, regarding intentional misrepresentation: The court erroneously believed that Insurance Law § 3105 requires proof of intent to deceive. As Jason notes, this is incorrect. Section 3105 requires only that a misrepresentation be material—it need not be intentional or fraudulent. The statute states that a misrepresentation is material if knowledge of the true facts “would have led to a refusal by the insurer to make such contract.” Intent is irrelevant; the question is whether the carrier would have acted differently had it known the truth.

Second, regarding the rate differential: The court correctly identified this as a fatal gap in Progressive’s proof. To establish materiality, the carrier must show that the misrepresentation would have affected its underwriting decision or the premium charged. The most straightforward way to prove this is through testimony establishing the rate differential between Rochester and Jamaica. Without evidence showing that premiums would have been different, the carrier cannot establish that the misrepresentation was material. The court’s observation that “there must be a price differential” but the carrier failed to prove one demonstrates this evidentiary failure.

Third, regarding the underwriting manual: Jason identifies an issue the court never addressed. In non-automatic-issue-policy (non-AIP) cases, carriers typically rely on underwriting manuals that establish the criteria for issuing policies and setting premiums. To prove that a misrepresentation would have led to different underwriting or pricing decisions, carriers must introduce their underwriting manual into evidence. Without this foundational evidence, the carrier’s assertions about what it would have done are speculative.

The court’s discussion of estoppel is interesting but, as Jason notes, generally irrelevant. Estoppel typically does not bar material misrepresentation defenses because allowing estoppel would undermine the fundamental principle that insurance contracts procured through material misrepresentation are void ab initio. However, the court’s concern that Progressive took no action when it learned the true address is understandable from an equitable standpoint—if the carrier knew the truth and continued to accept premiums, should it later be permitted to disclaim coverage?

Practical Implications

For insurance carriers asserting material misrepresentation defenses, this decision provides a clear roadmap of required proof: (1) evidence establishing what the insured stated in the application; (2) evidence establishing the truth; (3) testimony or documentary evidence establishing the rate differential or underwriting impact; and (4) in non-AIP cases, introduction of the underwriting manual showing the carrier’s criteria for issuing policies and setting premiums.

For healthcare providers defending against material misrepresentation defenses, the decision identifies specific evidentiary gaps to exploit. Providers should carefully review the carrier’s proof and move for directed verdict or dismissal if the carrier fails to establish the rate differential or introduce the underwriting manual.

Jason Tenenbaum’s observation that there are “too many moving pieces on these cases” reflects the complexity of material misrepresentation defenses. Carriers often assume that proving a false statement is sufficient, when in fact materiality requires additional proof that is frequently overlooked. This complexity creates opportunities for defense but also means that legitimate defenses may fail due to evidentiary oversights.

Related Articles

• Material Misrepresentation in Insurance Claims: New York Legal Guide
• Material Misrepresentation in Insurance Procurement: New York Law Protects Policyholders
• Identity Fraud in Insurance Policy Procurement: Long Island NYC Legal Guide
• Fraudulent procurement and preclusion